Albireo
Clinical trials sponsored by Albireo, explained in plain language.
Biopharmaceutical company focused on liver diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug shows promise for fatty liver – but early days
Disease control CompletedThis phase 2 trial tested elobixibat, a drug that blocks bile acid absorption in the gut, in 47 adults with nonalcoholic fatty liver disease (NAFLD) or its more severe form NASH. Participants received either elobixibat or a placebo for 16 weeks. The main goal was to see if the dr…
Phase 2 • Sponsor: Albireo • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug shows promise for rare childhood liver disease
Disease control CompletedThis study tested a drug called odevixibat (A4250) in 62 children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2, a rare liver disease that causes severe itching and bile buildup. The drug works by blocking the reabsorption of bile acids in the gut. The g…
Phase 3 • Sponsor: Albireo • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC